This technology offers a novel approach for new cancer treatments based on inhibiting HIF2α-related processes.
Background: Hypoxia-inducible factor 2α (HIF2α) transcription factor is involved in the adaptation of cancer cells (including clear cell renal cell carcinoma (ccRCC)) to low oxygen conditions (hypoxia). It plays a role in promoting tumor growth and angiogenesis. Pharmacologic inhibition of HIF2α offers a novel therapeutic strategy for cancers driven by HIF2α signaling. Belzutifan, a highly specific and well-tolerated HIF2α inhibitor, recently received FDA approval for the treatment of nonmetastatic renal cell carcinomas, pancreatic neuroendocrine tumors, and central nervous system hemangioblastomas from patients with von Hippel-Lindau disease, who carry VHL germline mutations.
Technology Overview: This technology is a selective HIF2α inhibitor that has a different mode of action compared to Belzutifan. It works by disrupting the binding of HIF2α from its molecular chaperone Hsp70. Additionally, this HIF2α inhibitor may potentially combat Belzutifan resistance in cancer patients. Compound-c2 binds to the PAS-B domain of HIF2α and disrupts its interaction with the molecular chaperone Heat shock protein-70 (Hsp70). This leads to proteasomal degradation of HIF2α and activation of apoptosis in ccRCC. This offers a promising alternative for addressing drug resistance and presents a unique approach to inhibiting HIF2α-related processes.
https://suny.technologypublisher.com/files/sites/adobestock_535202789.jpeg Photo for reference only, not a depiction of the invention.
Advantages: • Offers a promising alternative for addressing Belzutifan drug resistance. • Provides a unique approach in inhibiting HIF2α-related processes.
Applications: The primary application for this technology is developing cancer treatments.
Intellectual Property Summary: Patent pending
Stage of Development: TRL 3 – Experimental proof of concept